Summit Therapeutics Inc — Quarterly Financial Statistics (NASDAQ:SMMT) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Dividends

Quarterly Annual

Cash from operating activities 30.3 M48.67 M61.17 M66.74 M93.08 M101.94 M 322.93 M Cash from investing activities 108.61 M-83.48 M160.11 M150.81 M-71 K-136.54 M 174.31 M Cash from financing activities 204.14 M-23.61 M7.68 M2.22 M33.81 M573.82 M 617.53 M Free cash flow 30.24 M48.66 M60.75 M66.74 M93.01 M101.77 M 322.27 M

Noticias

RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View

H.C. Wainwright recorta el precio objetivo de Summit Therapeutics por incertidumbre en ensayos de China

H.C. Wainwright recorta precio objetivo de Summit por incertidumbre en China

H.C. Wainwright cuts Summit Therapeutics stock price target on China trial timing uncertainty

SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in Focus

Citizens reitera calificación de acciones de Summit Therapeutics por expansión de pipeline

Citizens reitera calificación de Summit Therapeutics por expansión

Citizens reiterates Summit Therapeutics stock rating on pipeline expansion

Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript

Summit Therapeutics Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:SMMT) 2026-02-23

Summit T4 2025: avances clínicos contrarrestan fallo del BPA del 389%

Summit T4 2025: avances clínicos eclipsados por caída de 389% en UPA